Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

作者：Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, Ana Verena Almeida Mendes, Alessandra R. Souza, Mariana B.V. Silveira, Suzete Nascimento Farias da Guarda, Maristela Miyamoto de Nobrega, Maria Isabel de Moraes Pinto, Isabela G. S. Gonzalez, Natalia Salvador, Marília Miranda Franco, Renata Navis de Avila Mendonça, Isabelle Silva Queiroz Oliveira, Bruno Solano de Freitas Souza, Mayara Fraga, Parvinder K. Aley, Sagida Bibi, Liberty Cantrell, Wanwisa Dejnirattisai, Xinxue Liu, Juthathip Mongkolsapaya, Piyada Supasa, Gavin Screaton, Teresa Lambe, Merryn Voysey, Andrew J. Pollard, Mustapha Bittaye, Danielle Woods, Sophie Davies, Holly Smith, Marta Ulaszewska, Helen Sanders, Reece Mabette, Sophie Vernon, Zara Valliji, Gracie Mead, Chitra Tejpal, Juyeon Park, Amy Beveridge, Ahmed Eldawi, Sally Felle, Mayara Fraga, Thaiane Muniz Martins, Claudia Loureiro Martins Medrado, Laiana Januse de Arruda Cordeiro Matos · 发表于：The Lancet · 年份：2022 · DOI：10.1016/s0140-6736(22)00094-0 · 被引用次数：467 · 研究领域：SARS-CoV-2 and COVID-19 Research、Animal Virus Infections Studies、COVID-19 Clinical Research Studies

INTRODUCTION: The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses. METHODS: RHH-001 is a phase 4, participant masked, two centre, safety and immunogenicity study of Brazilian adults (18 years and older) in São Paulo or Salvador who had received two doses of CoronaVac 6 months previously. The third heterologous dose was of either a recombinant adenoviral vectored vaccine (Ad26.COV2-S, Janssen), an mRNA vaccine (BNT162b2, Pfizer-BioNTech), or a recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine (AZD1222, AstraZeneca), compared with a third homologous dose of CoronaVac. Participants were randomly assigned (5:6:5:5) by a RedCAP computer randomisation system stratified by site, age group (18-60 years or 61 years and over), and day of randomisation, with a block size of 42. The primary outcome was non-inferiority of anti-spike IgG antibodies 28 days after the booster dose in the heterologous boost groups compared with homologous regimen, using a non-inferiority margin for the geometric mean ratio (heterologous vs homologous) of 0·67. Secondary outcomes included neutralising antibody titres at day 28, local and systemic reactogenicity profiles, adverse events, and serious adverse events. This study was registered with Registro Brasileiro de Ensaios Clínicos, number RBR-9nn3scw. FINDINGS: Between Aug 16, and Sept 1, ...